Zim Laboratories Limited

Company Profile

Zim Laboratories Limited had its IPO on under the ticker symbol ZIMLAB.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Zim Laboratories Limited has a staff strength of 525 employees.

Stock update

Shares of Zim Laboratories Limited opened at ₹120.15 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹115.4 - ₹124.5, and closed at ₹118.9.

This is a -2.22% slip from the previous day's closing price.

A total volume of 74,010 shares were traded at the close of the day’s session.

In the last one week, shares of Zim Laboratories Limited have slipped by -7.36%.

Zim Laboratories Limited's Key Ratios

Zim Laboratories Limited has a market cap of ₹6.20 billion, indicating a price to book ratio of 0 and a price to sales ratio of 0.

In the last 12-months Zim Laboratories Limited’s revenue was ₹3.73 billion with a gross profit of ₹1.67 billion and an EBITDA of ₹440.12 million. The EBITDA ratio measures Zim Laboratories Limited's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Zim Laboratories Limited’s operating margin was 7.81% while its return on assets stood at 6.45% with a return of equity of 13%.

In Q2, Zim Laboratories Limited’s quarterly earnings growth was a negative -95.3% while revenue growth was a negative 27.3%.

Zim Laboratories Limited’s PE and PEG Ratio

Forward PE

0

Trailing PE

31.9598

PEG

Its diluted EPS in the last 12-months stands at ₹3.98 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Zim Laboratories Limited’s profitability.

Zim Laboratories Limited stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.

Zim Laboratories Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

₹3.42 billion

Total Liabilities

₹1.11 billion

Operating Cash Flow

₹0

Capital Expenditure

₹0

Dividend Payout Ratio

0%

Zim Laboratories Limited ended 2024 with ₹3.42 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹3.42 billion while shareholder equity stood at ₹2.00 billion.

Zim Laboratories Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹1.11 billion in other current liabilities, in common stock, ₹1.41 billion in retained earnings and ₹1.69 million in goodwill. Its cash balance stood at ₹64.21 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹246.25 million.

Zim Laboratories Limited’s total current assets stands at ₹1.91 billion while long-term investments were ₹0 and short-term investments were ₹11.95 million. Its net receivables were ₹952.49 million compared to accounts payable of ₹582.39 million and inventory worth ₹537.06 million.

In 2024, Zim Laboratories Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.

Comparatively, Zim Laboratories Limited paid ₹0 in dividends in 2024.

Other key metrics

Current Trading Price

₹118.9

52-Week High

₹388

52-Week Low

₹67.45

Analyst Target Price

₹

Zim Laboratories Limited stock is currently trading at ₹118.9 per share. It touched a 52-week high of ₹388 and a 52-week low of ₹388. Analysts tracking the stock have a 12-month average target price of ₹.

Its 50-day moving average was ₹122.38 and 200-day moving average was ₹120.92 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 7578.1% of the company’s stock are held by insiders while 0% are held by institutions.